PMID- 36513897
OWN - NLM
STAT- MEDLINE
DCOM- 20231113
LR  - 20231113
IS  - 1619-0904 (Electronic)
IS  - 1434-7229 (Print)
IS  - 1434-7229 (Linking)
VI  - 26
IP  - 4
DP  - 2023 Dec
TI  - Removal performance of pre- and post-dilution online hemodiafiltration using 
      identical hemodiafilters in the same patients.
PG  - 309-315
LID - 10.1007/s10047-022-01379-4 [doi]
AB  - Online hemodiafiltration (OHDF) for renal replacement therapy has two modes: pre- 
      (pre-OHDF) and post-dilution OHDF (post-OHDF). To elucidate the precise 
      differences between the two modes, a clinical study was performed using the same 
      polysulfone hemodiafilters in the same patients. Eight patients were treated with 
      ABH()-22PA for 6 weeks: 3 weeks of pre-OHDF (with substitution volumes of 24, 
      36, and 48 L) and 3 weeks of post-OHDF (6, 8, and 10 L). The reduction ratios of 
      urea, uric acid (UA), creatinine (CRE), inorganic phosphorus (iP), 
      beta-2-microglobulin (beta(2)-MG), and alpha-1-microglobulin (alpha(1)-MG) were 
      evaluated. The removal amounts of beta(2)-MG, alpha(1)-MG, and albumin were also 
      evaluated by analyzing the spent dialysis fluids. The types and numbers of 
      adverse events (AEs) and device malfunctions were recorded. The reduction ratios 
      of urea, UA, CRE, iP, and beta(2)-MG were comparable among all conditions, while 
      that of alpha(1)-MG tended to be slightly higher in post-OHDF than in pre-OHDF. The 
      removal amounts of alpha(1)-MG and albumin in pre-OHDF and post-OHDF were 
      significantly greater with the maximum substitution volume than with the minimum 
      volume. However, the selective removal indices, which were obtained by dividing 
      the amount of alpha(1)-MG removed by the albumin level, tended to be slightly higher 
      in pre- than in post-OHDF. No device-related AEs or device malfunctions occurred 
      in either mode. No significant differences in inflammatory responses, evaluated 
      by high-sensitivity C-reactive protein and interleukin-6, were observed. This 
      study provides removal performance and safety data regarding the application of 
      ABH-22PA for pre- and post-OHDF.
CI  - (c) 2022. The Author(s).
FAU - Okada, Kazuyoshi
AU  - Okada K
AD  - Department of Nephrology, Kawashima Hospital, 6-1 Kitasakoichibancho, Tokushima, 
      Tokushima, 770-0011, Japan. kokada@khg.or.jp.
FAU - Michiwaki, Hiroyuki
AU  - Michiwaki H
AD  - Department of Clinical Engineering, Kawashima Hospital, Tokushima City, 
      Tokushima, Japan.
FAU - Mori, Hiroaki
AU  - Mori H
AD  - Department of Clinical Engineering, Kawashima Hospital, Tokushima City, 
      Tokushima, Japan.
FAU - Tashiro, Manabu
AU  - Tashiro M
AD  - Department of Nephrology, Kawashima Hospital, 6-1 Kitasakoichibancho, Tokushima, 
      Tokushima, 770-0011, Japan.
FAU - Inoue, Tomoko
AU  - Inoue T
AD  - Department of Nephrology, Kawashima Hospital, 6-1 Kitasakoichibancho, Tokushima, 
      Tokushima, 770-0011, Japan.
FAU - Shima, Hisato
AU  - Shima H
AD  - Department of Nephrology, Kawashima Hospital, 6-1 Kitasakoichibancho, Tokushima, 
      Tokushima, 770-0011, Japan.
FAU - Ohshima, Koji
AU  - Ohshima K
AUID- ORCID: 0000-0003-0564-1096
AD  - Asahi Kasei Medical Co., Ltd., 1-1-2 Yurakucho, Chiyoda-Ku, Tokyo, 100-0006, 
      Japan. oshima.kb@om.asahi-kasei.co.jp.
FAU - Minakuchi, Jun
AU  - Minakuchi J
AD  - Department of Nephrology, Kawashima Hospital, 6-1 Kitasakoichibancho, Tokushima, 
      Tokushima, 770-0011, Japan.
FAU - Kawashima, Shu
AU  - Kawashima S
AD  - Department of Nephrology, Kawashima Hospital, 6-1 Kitasakoichibancho, Tokushima, 
      Tokushima, 770-0011, Japan.
LA  - eng
PT  - Journal Article
DEP - 20221214
PL  - Japan
TA  - J Artif Organs
JT  - Journal of artificial organs : the official journal of the Japanese Society for 
      Artificial Organs
JID - 9815648
RN  - 0 (Dialysis Solutions)
RN  - 0 (Albumins)
RN  - 8W8T17847W (Urea)
RN  - 0 (beta 2-Microglobulin)
RN  - AYI8EX34EU (Creatinine)
SB  - IM
MH  - Humans
MH  - *Hemodiafiltration
MH  - Renal Dialysis
MH  - Dialysis Solutions
MH  - Albumins
MH  - Urea
MH  - beta 2-Microglobulin
MH  - Creatinine
PMC - PMC10635926
OTO - NOTNLM
OT  - Albumin leakage
OT  - Alpha-1-microglobulin
OT  - Online hemodiafiltration
OT  - Post-dilution
OT  - Pre-dilution
COIS- The authors declare the following potential conflicts of interest with respect to 
      the research, authorship, and/or publication of this article: K. Ohshima is an 
      employee of Asahi Kasei Medical Co., Ltd.
EDAT- 2022/12/14 06:00
MHDA- 2023/11/13 06:43
PMCR- 2022/12/14
CRDT- 2022/12/13 23:40
PHST- 2022/04/21 00:00 [received]
PHST- 2022/11/30 00:00 [accepted]
PHST- 2023/11/13 06:43 [medline]
PHST- 2022/12/14 06:00 [pubmed]
PHST- 2022/12/13 23:40 [entrez]
PHST- 2022/12/14 00:00 [pmc-release]
AID - 10.1007/s10047-022-01379-4 [pii]
AID - 1379 [pii]
AID - 10.1007/s10047-022-01379-4 [doi]
PST - ppublish
SO  - J Artif Organs. 2023 Dec;26(4):309-315. doi: 10.1007/s10047-022-01379-4. Epub 
      2022 Dec 14.